A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the
safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel
T-Cell bispecific (TCB), MBS303, administered by intravenous (IV) infusion in participants
with relapsed or refractory B-cell NHL. This entry-to-human study consists of 2 parts: a dose
escalation part (Phase I) and an expansion part (Phase Ⅱ)